Pharma Contract Manufacturers
CDMO stocks in focus: Laurus Labs hits new high; Sai Life Sciences gains 2%
In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, the BSE Sensex has slipped 4.2 per cent.
 "CDMO stocks in focus: Laurus Labs hits new high; Sai Life Sciences gains 2%")
Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs
Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.
 "Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs")
Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?
In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent
 "Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?")
Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat
Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.
 "Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat")
Onesource Specialty Pharma up 5% in weak market; rallies 21% in one week
The company will continue to derive strength from the existence of experienced promoters and positive outlook for the GLP1 segment, which is expected to yield revenue to the company from FY27 onwards.
 "Onesource Specialty Pharma up 5% in weak market; rallies 21% in one week")
Acutaas Chemicals zooms 50% in 2 months, hits new high; here's why
In the past one month, the stock price of pharmaceuticals company has gained 15 per cent, as compared to 11 per cent decline in the BSE Sensex.
 "Acutaas Chemicals zooms 50% in 2 months, hits new high; here's why")
Laurus Labs jumps 4% on huge volumes; Motilal projects 30% further upside
Motilal Oswal remains positive on Laurus due to its strengthening position in gaining CDMO contracts, the addition of a growth lever in the generics space, and a steady ARV business.
 "Laurus Labs jumps 4% on huge volumes; Motilal projects 30% further upside")
Sai Life hits record high in weak market; rebounds 5% from day's low
Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.
 "Sai Life hits record high in weak market; rebounds 5% from day's low")
Laurus Labs soars 8% in 2 days, nears record high; analysts see more upside
The management expects better Q4 and a decent overall growth in FY27
 "Laurus Labs soars 8% in 2 days, nears record high; analysts see more upside")
Sai Life rallies 5%, hits all-time high; what's driving pharma stock?
In H1FY26, total revenue of the Sai Life Sciences increased by 53% YoY at ₹1,034 crore, driven by healthy growth across both the CRO and the CDMO business.
 "Sai Life rallies 5%, hits all-time high; what's driving pharma stock?")
Laurus Labs soars 6% in 2 days, market cap tops ₹ 50,000 crore; here's why
At 11:29 AM, Laurus Labs' stock was quoting 2 per cent higher at ₹943.15 on the BSE, commanding an m-cap of ₹50,913 crore, exchange data shows
Small contract manufacturers wait to take a shot at Covid vaccines
A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors
 "Small contract manufacturers wait to take a shot at Covid vaccines")
Pharma contract manufacturers hit as IPM slows down
Contract manufacturers claim that at least 40-60% of pharmaceutical manufacturing in the country is outsourced by big pharma
 "Pharma contract manufacturers hit as IPM slows down")